Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · IEX Real-Time Price · USD
6.07
0.00 (0.00%)
At close: Jul 5, 2022 12:00 AM
6.37
+0.30 (4.94%)
Pre-market:
Jul 6, 2022 8:45 AM EDT
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.
The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.
The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Milestone Pharmaceuticals Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 29 |
Contact Details
Address:
1111 Dr. Frederik-Philips Boulevard Montreal, QC H4M 2X6 Canada | |
| Phone | 514 336 0444 |
| Website | milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President and Director |
| Amit Hasija | Chief Financial Officer and Executive Vice President of Corporate Development |
| Dr. Francis Plat FAHA, M.D. | Chief Scientific Officer |
| Dr. Philippe Douville | Founder, Strategic Advisor and Member of Scientific Advisory Board |
| Jeff Nelson | Chief Operating Officer |
| Kimberly Sheehan | Vice President of Human Resources |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor and Member of the Scientific Advisory Board |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
| Lorenz Muller | Chief Commercial Officer |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 1, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 12, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 2, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 2, 2022 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2022 | PRE 14A | Other preliminary proxy statements |
| Mar 24, 2022 | 8-K | Current report |
| Mar 24, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Mar 23, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Mar 23, 2022 | 4 | Statement of changes in beneficial ownership of securities |